On February 25, BGI Group（Beijing Genomics Institute）and China Biotech Service Holdings Ltd. (referred to as "China Biotech Service") signed a strategic cooperation framework agreement to deepen collaboration in the fields of tumor precision diagnosis, treatment, and technological research and development.
In the future, both parties aim to leverage their respective resources and strengths for comprehensive collaboration in the full-cycle management of malignant tumors, advancing cancer prevention and control, and contributing to the development of a healthier China by reducing the incidence and mortality rates of malignant tumors.
